283 related articles for article (PubMed ID: 24727144)
1. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
Siebert N; Eger C; Seidel D; Jüttner M; Lode HN
J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144
[TBL] [Abstract][Full Text] [Related]
2. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
[TBL] [Abstract][Full Text] [Related]
3. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
[TBL] [Abstract][Full Text] [Related]
4. Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.
Siebert N; Seidel D; Eger C; Jüttner M; Lode HN
PLoS One; 2014; 9(9):e107692. PubMed ID: 25226154
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response.
Lode HN; Schmidt M; Seidel D; Huebener N; Brackrock D; Bleeke M; Reker D; Brandt S; Mueller HP; Helm C; Siebert N
Cancer Immunol Immunother; 2013 Jun; 62(6):999-1010. PubMed ID: 23591980
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.
Siebert N; Eger C; Seidel D; Jüttner M; Zumpe M; Wegner D; Kietz S; Ehlert K; Veal GJ; Siegmund W; Weiss M; Loibner H; Ladenstein R; Lode HN
MAbs; 2016; 8(3):604-16. PubMed ID: 26785755
[TBL] [Abstract][Full Text] [Related]
7. Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.
Siebert N; Troschke-Meurer S; Marx M; Zumpe M; Ehlert K; Gray J; Garaventa A; Manzitti C; Ash S; Klingebiel T; Beck J; Castel V; Valteau-Couanet D; Loibner H; Ladenstein R; Lode HN
Cancers (Basel); 2018 Oct; 10(10):. PubMed ID: 30336605
[TBL] [Abstract][Full Text] [Related]
8. Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.
Eger C; Siebert N; Seidel D; Zumpe M; Jüttner M; Brandt S; Müller HP; Lode HN
PLoS One; 2016; 11(3):e0150479. PubMed ID: 26967324
[TBL] [Abstract][Full Text] [Related]
9. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
Mueller I; Ehlert K; Endres S; Pill L; Siebert N; Kietz S; Brock P; Garaventa A; Valteau-Couanet D; Janzek E; Hosten N; Zinke A; Barthlen W; Varol E; Loibner H; Ladenstein R; Lode HN
MAbs; 2018 Jan; 10(1):55-61. PubMed ID: 29120699
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
Sondel PM; Hank JA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
[TBL] [Abstract][Full Text] [Related]
11. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
[TBL] [Abstract][Full Text] [Related]
12. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.
Albertini MR; Gan J; Jaeger P; Hank JA; Storer B; Schell K; Rivest T; Surfus J; Reisfeld RA; Schiller JH; Sondel PM
J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):278-95. PubMed ID: 8877722
[TBL] [Abstract][Full Text] [Related]
13. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD
Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN
Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486
[TBL] [Abstract][Full Text] [Related]
15. Reduction of CD11b
Siebert N; Zumpe M; von Lojewski L; Troschke-Meurer S; Marx M; Lode HN
Oncoimmunology; 2020 Oct; 9(1):1836768. PubMed ID: 33150046
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin?
Uttenreuther-Fischer MM; Krüger JA; Fischer P
J Immunol; 2006 Jun; 176(12):7775-86. PubMed ID: 16751426
[TBL] [Abstract][Full Text] [Related]
17. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.
Yu AL; Uttenreuther-Fischer MM; Huang CS; Tsui CC; Gillies SD; Reisfeld RA; Kung FH
J Clin Oncol; 1998 Jun; 16(6):2169-80. PubMed ID: 9626218
[TBL] [Abstract][Full Text] [Related]
19. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma.
Kremens B; Hero B; Esser J; Weinel P; Filger-Brillinger J; Fleischhack G; Graf N; Grüttner HP; Niemeyer C; Schulz A; Wickmann L; Berthold F
Cancer Immunol Immunother; 2002 Apr; 51(2):107-10. PubMed ID: 11904735
[TBL] [Abstract][Full Text] [Related]
20. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen.
Förster-Waldl E; Riemer AB; Dehof AK; Neumann D; Brämswig K; Boltz-Nitulescu G; Pehamberger H; Zielinski CC; Scheiner O; Pollak A; Lode H; Jensen-Jarolim E
Mol Immunol; 2005 Feb; 42(3):319-25. PubMed ID: 15589320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
